For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 12

Based on the information you provided, we found the following studies.

  • Phase I/II Trial of experimental drug ganetespib in combination with the mTOR inhibitor sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumors (MPNST) Study purpose:find highest safe dose, side effects and any benefits of ganetespib when given with sirolimus; test whether 3D-MRI is better at seeing MPNST than traditional scans This study is researching all of the following topics: Cancerous bone tumor, Osteosarcoma Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Improving Adherence to Oral Cancer Agents and Self-Care of Symptoms Using an IVR The purpose of the study is to: (1) determine if daily reminders will help patients take their anti-cancer pills as prescribed and; (2) test strategies to manage symptoms between doctor office visits. We are hoping to learn better ways to support patients who are prescribed oral anti-cancer pills. This study is researching all of the following topics: Breast cancer Colon Cancer ( Malignant tumor of colon ) Melanoma Pancreatic cancer Prostate cancer Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 21 years old
  • A Phase 1/ 2 Study of BMN 673, an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies Study goals: find highest safe dose of temozolomide that can be given with experimental drug BMN 673 without causing severe side effects; learn side effects BMN 673 can cause; learn side effects BMN 673/temozolomide combination can cause; learn how your body handles BMN 673/temozolomide combination This study is researching all of the following topics: Brain cancer Leukemia Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 21 years old
    • More than 1 years old
  • A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma Study purpose: learn if combination treatment of experimental drug niraparib and FDA approved temozolomide is safe and effective in Ewing sarcoma patients no longer benefiting from available standard therapy: find highest safe doses for both drugs, learn about side effects, evaluate usefullness. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 13 years old
  • Multicenter, Randomized, Open-Label Phase 3 Study: Aldoxorubicin Compared to Investigators Choice in Subjects w/ Soft Tissue Sarcoma Who Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy The purpose of this study is to see if the investigational drug, aldoxorubicin, will slow the growth of your cancer, evaluate the side effects of the treatment, and determine how safe and effective aldoxorubicin is compared to other approved drugs for your condition. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 15 years old
  • Phase I safety study of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies This study is being done to learn whether treatment with Clostridium novyi-NT spores (NT refers to non-toxin producing) is safe and effective in patients with advanced cancers that can no longer be controlled with standard therapy or cancers for which there is no standard effective treatment. This study is researching all of the following topics: Adrenal cancer BCC, Basal cell skin cancer Bladder cancer Bone cancer Breast cancer Cervical cancer Colon Cancer ( Malignant tumor of colon ) Esophagus cancer Fallopian tube cancer HCC, Liver cancer Kidney Cancer ( Malignant tumor of kidney ) Laryngeal cancer, Cancer of the larynx, Voice box cancer Lung cancer Lymphoma NPC, Nasal cancer Oral / Mouth cancer Ovarian cancer Pancreatic cancer Prostate cancer Salivary Gland Cancer Sarcoma Squamous cell skin cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma. The purpose of this study is to test the effectiveness and safety of gemcitabine and pazopanib compared with gemcitabine and docetaxel in participants with soft tissue sarcoma.We also want to know your view of how your life has been affected by cancer and these treatments, i.e., “quality of life”. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma The goal of this study is to find out what effects, good and/or bad, pazopanib has on you, and your angiosarcoma, which cannot be treated with surgery. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A randomised phase III study of masitinib versus sunitinib in patients with GIST after progression with imatinib The study aims to see if masitinib is better or safer than the standard treatment for GIST called sunitinib (Sutent ®). Sunitinib is used to treat advanced kidney cancer, pancreatic cancer, and GIST. Masitinib and sunitinib will be given to those with GIST whose disease does not respond to imatinib. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • SARC016 Phase 2 study of the mTOR inhibitor everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 (NF1) related refractory MPNST The purpose of the study is to evaluate whether the combination of everolimus and bevacizumab will stop MPNST tumors from growing or shrink them. This study may help determine if everolimus and bevacizumab may be useful in future trials that are specifically designed to treat MPNST. This study is researching all of the following topics: Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 18 years old
Showing 1-10 of 12 studies
Show more studies